#3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

PANZNER 1 PCT

SERIAL NO.:

09/831,975

FILED:

MAY 16, 2001

TITLE:

NANOCAPSULES AND METHOD OF PRODUCING SAME

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

ATT: BOX PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

SIR:

This is in response to the Notification of Missing
Requirements Under 35 U.S.C. 371 in the U.S. Designated Office
dated June 28, 2001.

This Notification states that this patent application fails to contain a "Sequence Listing".

After reviewing the above identified patent application, the undersigned attorneys are of the opinion that no "Sequence Listing" is required in this patent application. Therefore it is requested that this requirement for a "Sequence Listing" in the present patent application be withdrawn.

Specifically, the present invention relates to producing
R:\Marie\ERF\PANZNER.wpd

liposomes, based upon organic chemistry and/or pharmaceutical chemistry. The present Specification is not directed to biotechnology and does not set forth any examples of an amino acid sequence or of a nucleotide base sequence.

For all these reasons, it is respectfully submitted that the requirement to provide a "Sequence Listing" does not apply to the present patent application, and should be withdrawn.

Respectfully submitted,

PANZNER 1 PCT

COLLARD & ROE, P.C. 1077 Northern Boulevard Roslyn, New York 11576

Allison C. Colla

Rea. No.

Edward R. Freedman, Reg. No. 26,048

Attorneys for Applicants

(516) 365-9802

Enclosure: Copy of Notification of Missing Requirements

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, on the date indicated above, and is addressed to the Ass't. Commissioner for Patents, Washington, D.C. 20231 on August 22, 2001



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 2023

The state of the s					www.ust
U.S. APPLICATION NO.		FIRST NAMED APPLICANT		ATT	TY. DOCKET NO.
09/831975	P	ANZNER	S	PAI	NZNER PCT
			INTERNA	TIONAL APPL	JCATION NO.
COLLARD & ROE		1	PC	T/EP99/	09744
1077 NORTHERN BOULEVAR	D				•
ROSLYN, NY 11576 1696	_		I.A. FILING D	ATE	PRIORITY DATE
			15 NOV	99	17 NOV 98
1. The following items have been s	DESIGNATION ubmitted by the a Office (37 CFR 1.	ED/ELECTED OFF	ICE (DO/EO/ United States Patent ce (37 CFR 1.495)	71 IN T US) and Trad	
Copy of the international		Translation of the inte			
Oath or Declaration of i		Translation of Article	: 19 amendments in	ito English	h.
Copy of Article 19 ame	ndments.	Other:			
Priority Document.					
L!	•	on Report in English and i			
Translation of Annexes	to the Internation	al Preliminary Examination	on Report into Eng	lish.	,
2. Applicant has requested early the indicated items in paragraph 3 be prior to 20 or 30 months from the pr U.S. Basic National Fee	elow. The Basic literates date to avo	National Fee and the copy	of the international	ving indica il applicati	ated items and/or ion must be filed
		an analysis and from the terms of		··	
The current translation. b. Processing fee for property appropriate 20 or 2 or 2 or 3 or 4	plication into Engopriate 20 or 30 ration is defective oviding the transl 30 months from the first open than the first open that the first open than the first open th	clish. A processing fee wimonth from the priority of for the reasons indicated of the application and the priority date (37 CFR to compliance with 37 CFR to the ternational application mutted later than the appropriase not comply with 37 CFR EO/917. Exclaration later than the appropriate comply with 37 CFR in the comply with 37 CFR EO/917. Exclaration later than the appropriate control of the complex control of the control	all be required if substate. In the attached Not door the Annexes I 1.492(f)). It 1.497(a) and (b), and the annexes I 1.497(a) and (b) for an an annexe I 1.497(a) and (b) for an annexe I 1.497(a) and (c) for an annexe I 1.497(a) and (c) for an annexe I 1.497(a) and (c) for an annexe I 1.497(a) and (d) for an annexe I 1.497(a) annexe I 1.497(binitied ice of Def ater than to properly it mal filing his from the for the real months fro quired mul laims for See attact D WITHII FR 1.495	fective the identifying date). A the priority the sons om the ltiple dependent which fees are thed N TWO (2) applies) FROM
THE PRIORITY DATE FOR THE RESPOND WILL RESULT IN AB	BANDONMENT	•			
1.136(a). 6. If box 3a or 3c is checked, a tran Annexes will be cancelled. A proces 7. The Article 19 amendments ar or 30 (37 CFR 1.495(d)) months from	ssing fee will be r e cancelled since	required if submitted later a translation was not prov	than 20 or 30 mon	ths from t	the priority date.
Applicant is reminded that any commaddress given in the heading and incl				iust be ma	ailed to the
A copy of l Enclosed: ☐ PCT/DO/EO/917 ☐ PTO-875	☐ Notic	AUST be returned to of Defective Translation DO/EO/920			
	<u>[e]</u> - 3	Bai	rbara A. Campt		
FORM PCT/DO/EO/905 (March 200	01)	Telephone	703-305-3631		

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

			www.usp.p.g	
U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY. DOCKET NO.	
09/831975	PANZNER	S	PANZNER PCT INTERNATIONAL APPLICATION NO.	
		INTERNATIO		
COLLARD & ROE 1077 NORTHERN BOULEVARD		PCT/E	P99/09744	
ROSLYN, NY 11576 1696		I.A. FILING DATE	PRIORITY DATE	
		15 NOV 99	17 NOV 98	
		DATE MAILED	28 JUN 2001	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825. This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c). A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:
APPLICANT MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help, (703) 287-0200, for PatentIn software help.

Barbara A. Campbell

Telephone: 703-305-3631